Mutations associated with HNPCC predisposition -- Update of ICG-HNPCC/INSiGHT mutation database - PubMed (original) (raw)

Review

Mutations associated with HNPCC predisposition -- Update of ICG-HNPCC/INSiGHT mutation database

Päivi Peltomäki et al. Dis Markers. 2004.

Abstract

In 1994, the International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer (ICG-HNPCC) established an international database of mutations identified in families with Lynch (HNPCC) syndrome. The data are publicly available at http://www.nfdht.nl. The information stored in the database was systematically analyzed in 1997, and at that time, 126 different predisposing mutations were reported affecting the DNA mismatch repair genes MSH2 and MLH1 and occurring in 202 families. In 2003, the ICG-HNPCC and the Leeds Castle Polyposis Group (LCPG) merged into a new group, INSiGHT (International Society for Gastrointestinal Hereditary Tumors). The present update of the database of DNA mismatch repair gene mutations of INSiGHT includes 448 mutations that primarily involve MLH1 (50%), MSH2 (39%), and MSH6 (7%) and occur in 748 families from different parts of the world.

PubMed Disclaimer

Similar articles

• Molecular characterization of the spectrum of genomic deletions in the mismatch repair genes MSH2, MLH1, MSH6, and PMS2 responsible for hereditary nonpolyposis colorectal cancer (HNPCC).
  van der Klift H, Wijnen J, Wagner A, Verkuilen P, Tops C, Otway R, Kohonen-Corish M, Vasen H, Oliani C, Barana D, Moller P, Delozier-Blanchet C, Hutter P, Foulkes W, Lynch H, Burn J, Möslein G, Fodde R. van der Klift H, et al. Genes Chromosomes Cancer. 2005 Oct;44(2):123-38. doi: 10.1002/gcc.20219. Genes Chromosomes Cancer. 2005. PMID: 15942939
• Heterozygous mutations in PMS2 cause hereditary nonpolyposis colorectal carcinoma (Lynch syndrome).
  Hendriks YM, Jagmohan-Changur S, van der Klift HM, Morreau H, van Puijenbroek M, Tops C, van Os T, Wagner A, Ausems MG, Gomez E, Breuning MH, Bröcker-Vriends AH, Vasen HF, Wijnen JT. Hendriks YM, et al. Gastroenterology. 2006 Feb;130(2):312-22. doi: 10.1053/j.gastro.2005.10.052. Gastroenterology. 2006. PMID: 16472587
• Mutations predisposing to hereditary nonpolyposis colorectal cancer.
  Peltomäki P, de la Chapelle A. Peltomäki P, et al. Adv Cancer Res. 1997;71:93-119. doi: 10.1016/s0065-230x(08)60097-4. Adv Cancer Res. 1997. PMID: 9111864 Review.
• Molecular basis of HNPCC: mutations of MMR genes.
  Papadopoulos N, Lindblom A. Papadopoulos N, et al. Hum Mutat. 1997;10(2):89-99. doi: 10.1002/(SICI)1098-1004(1997)10:2<89::AID-HUMU1>3.0.CO;2-H. Hum Mutat. 1997. PMID: 9259192 Review.

Cited by

• Gastrointestinal Malignancy: Genetic Implications to Clinical Applications.
  Trembath HE, Yeh JJ, Lopez NE. Trembath HE, et al. Cancer Treat Res. 2024;192:305-418. doi: 10.1007/978-3-031-61238-1_15. Cancer Treat Res. 2024. PMID: 39212927 Review.
• Key role of phosphorylation sites in ATPase domain and Linker region of MLH1 for DNA binding and functionality of MutLα.
  Firnau MB, Plotz G, Zeuzem S, Brieger A. Firnau MB, et al. Sci Rep. 2023 Aug 2;13(1):12503. doi: 10.1038/s41598-023-39750-x. Sci Rep. 2023. PMID: 37532794 Free PMC article.
• Pulmonary Artery Intimal Sarcoma in a Patient with Lynch Syndrome: Response to an Immune Checkpoint Inhibitor.
  Mounai Y, Yoshida T, Ito S, Fukuda K, Shimazu K, Taguchi D, Shinozaki H, Takagi D, Imai K, Yamamoto H, Minamiya Y, Nanjyo H, Shibata H. Mounai Y, et al. Case Rep Oncol. 2023 Jan 27;16(1):21-29. doi: 10.1159/000528682. eCollection 2023 Jan-Dec. Case Rep Oncol. 2023. PMID: 36743879 Free PMC article.
• Validity of pathological diagnosis for early colorectal cancer in genetic background.
  Okimoto K, Hirotsu Y, Arai M, Amemiya K, Akizue N, Ohta Y, Taida T, Saito K, Ohyama H, Matsumura T, Nishimura M, Matsushita K, Matsusaka K, Oyama T, Mochizuki H, Chiba T, Kato J, Ikeda JI, Yokosuka O, Kato N, Omata M. Okimoto K, et al. Cancer Med. 2023 Apr;12(7):8490-8498. doi: 10.1002/cam4.5596. Epub 2023 Feb 3. Cancer Med. 2023. PMID: 36734304 Free PMC article.
• Case report: Complete response to pembrolizumab in a liver metastatic colon adenocarcinoma patient with a novel likely pathogenic germline MSH2 mutation.
  Xu Y, Li Q, Zhao J, Ni X, Li P, Hu W. Xu Y, et al. Front Immunol. 2022 Nov 28;13:1064488. doi: 10.3389/fimmu.2022.1064488. eCollection 2022. Front Immunol. 2022. PMID: 36518767 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Hindawi Limited
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal